Nova Eye Medical Limited

Equities

EYE

AU0000094252

Advanced Medical Equipment & Technology

Market Closed - Australian S.E. Other stock markets 01:33:14 2024-06-06 EDT			5-day change	1st Jan Change
0.23 ^AUD	-2.13%		-4.17%	-4.17%

03-15	Nova Eye Medical Completes Retail Entitlement Offer	MT
02-22	Nova Eye Medical Limited Reports Earnings Results for the Half Year Ended December 31, 2023	CI

Ellex Medical Lasers Limited Provides Unaudited Earnings Guidance for the Six Months Ended 31 December 2017

February 04, 2018

Ellex Medical Lasers Limited provided unaudited earnings guidance for the six months ended 31 December 2017. For the period, the company expects revenue to be AUD 38.2 million, and negative EBITDA to be AUD 0.9 million.

Latest news about Nova Eye Medical Limited

Nova Eye Medical Completes Retail Entitlement Offer	03-14	MT
Nova Eye Medical Limited Reports Earnings Results for the Half Year Ended December 31, 2023	02-22	CI
Nova Eye Medical Completes Placement, Institutional Entitlement Offer; Shares Plunge 22%	02-13	MT
Nova Eye Medical Launches AU$8 Million Capital Raising for Glaucoma Surgical Device Business Expansion	02-11	MT
Nova Eye Medical's US Sales of Glaucoma Surgical Devices Surge in H2 2023; Shares Jump 13%	01-07	MT
Lower Oil, Metal Prices Pull Down Australian Shares	12-29	MT
Nova Eye Medical Jumps 37% After Withdrawal of Proposed Changes in US Medicare Coverage	12-28	MT
Nova Eye Medical Announces Deferral of Proposed US Medicare Changes; Shares Jump 13%	12-07	MT
Transcript : Nova Eye Medical Limited, 2023 Earnings Call, Aug 28, 2023	23-08-27
Nova Eye Medical Limited Reports Earnings Results for the Full Year Ended June 30, 2023	23-08-27	CI
Nova Eye Medical's Glaucoma Surgical Devices Sales in the US Hits $2.2 Million in Three Months to July; Shares Jump 8%	23-08-01	MT
Transcript : Nova Eye Medical Limited Presents at ShareCafe Small Cap Hidden Gems Webinar, May-19-2023 12:30 PM	23-05-18
US FDA Approves Nova Eye Medical's Canaloplasty Device for Glaucoma Surgery for US Launch; Shares Jump 20%	23-03-30	MT
Nova Eye Medical Raises AU$8 Million for Expansion of Glaucoma Surgical Devices	23-03-01	MT
Nova Eye Medical Limited Reports Earnings Results for the Half Year Ended December 31, 2022	23-02-28	CI
Nova Eye Medical Says Studies for 2RT as Potential CSR Therapy Begin	23-01-24	MT
Nova Eye Medical Limited Announces New, Additional Clinical Application for 2RT Currently Under Investigation	23-01-24	CI
US FDA Pushes Expected Clearance for Nova Eye Medical's Device to 2023	22-12-12	MT
Nova Eye Medical Limited Receives Feedback from the US Food & Drug Administration in Relation to Its 510(K) Submission for Marketing Clearance of the Company's New iTrack Advance Canaloplasty Device in the USA	22-12-11	CI
Nova Eye Medical Limited Appoints Daniel Webb as Director	22-11-16	CI
International Researchers Join in Nova Eye Medical’s Study on Eye Laser Therapy	22-10-25	MT
Nova Eye Medical Limited Completes Initial Recruitment of Investigator Sites	22-10-23	CI
Nova Eye Medical Limited Reports Earnings Results for the Full Year Ended June 30, 2022	22-08-25	CI
Nova Eye Medical Expects 0.5% Uptick in FY22 Sales of Glaucoma Surgical Devices Segment	22-07-08	MT
Nova Eye Medical Starts Commercial Roll-out of Canaloplasty Device in Europe, Asia Pacific; Shares Jump 5%	22-06-07	MT

Chart Nova Eye Medical Limited

Duration

Period

More charts

Company Profile

Nova Eye Medical Limited is an Australia-based medical technology company that develops, manufactures, and sells a portfolio of proprietary ophthalmic treatment technologies and devices. The Company operates through three segments: AlphaRET, and Glaucoma surgical devices. The Companyâs AlphaRET segment is responsible for the commercialization of the 2RT ophthalmic laser, which is an ophthalmic laser developed for the therapy of patients in the early to intermediate stages of age-related macular degeneration (AMD). 2RT is a patented nano-pulse laser device that rejuvenates retinal structures compromised by AMD. The Glaucoma Surgical Devices segment includes the designing, manufacturing, marketing, and sale of the iTrack, iTrack Advance and the Molteno3 glaucoma surgical device. The Molteno3 glaucoma drainage device platform is designed to enhance surgical utility and optimize clinical outcomes for long-term intraocular pressure (IOP) control in cases of severe glaucoma.

Sector

Advanced Medical Equipment & Technology

Calendar

2024-08-27 - Q4 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for Nova Eye Medical Limited

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

0.235 AUD

Average target price

0.52 AUD

Spread / Average Target

+121.28%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Advanced Medical Equipment & Technology

	1st Jan change	Capi.
NOVA EYE MEDICAL LIMITED	-4.17%	35.7M
THERMO FISHER SCIENTIFIC	+8.38%	220B
DANAHER CORPORATION	+15.78%	198B
BOSTON SCIENTIFIC CORPORATION	+31.27%	112B
SIEMENS HEALTHINEERS AG	+4.98%	66.17B
EDWARDS LIFESCIENCES CORPORATION	+14.19%	52.47B
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	+4.70%	50.77B
AGILENT TECHNOLOGIES, INC.	-3.93%	38.97B
GE HEALTHCARE TECHNOLOGIES INC.	-0.47%	35.13B
RESMED, INC.	+23.96%	31.32B

Other Advanced Medical Equipment & Technology